Metformin's Hidden Cost: How It Disrupts Waste Clearance and Fuels Chronic Inflammation

Gluconeogenesis is conventionally understood as the liver's glucose-making engine during fasting. This review reframes it as also a sophisticated metabolic waste-disposal network, operating through two interorgan cycles. The Cori cycle shuttles lactate from peripheral tissues (muscle, red blood cells) to the liver, where it is converted back to glucose — clearing a potentially acidifying metabolite. The Alanine cycle carries nitrogen waste from muscle proteolysis to the liver, feeding it into the urea cycle to produce excreted urea. Together, these cycles prevent lactic acidosis, ammonia toxicity, and ROS-driven oxidative stress — and in doing so, suppress inflammatory signaling pathways including HIF-1α and NF-κB.

Metformin inhibits hepatic gluconeogenesis through a well-characterized cascade: it accumulates in hepatocytes via OCT1 transporters, inhibits mitochondrial respiratory chain complex I (NADH:ubiquinone oxidoreductase), raises the AMP/ATP ratio, and activates AMPK (phosphorylated at Thr172 by LKB1). Activated AMPK then phosphorylates CBP at Ser436, disrupting CREB-CBP interactions and repressing transcription of PEPCK and G6Pase — the key gluconeogenic enzymes. AMPK also promotes nuclear exclusion of CRTC2, compounding transcriptional suppression. The drug preferentially suppresses lactate- and glycerol-derived gluconeogenesis more than alanine-derived flux, meaning Cori cycle disruption is more acute than Alanine cycle impairment, though both are affected.

The authors construct a detailed inflammatory cascade downstream of metabolite accumulation. Excess lactate stabilizes HIF-1α by competing with α-ketoglutarate-dependent prolyl hydroxylases, inducing transcription of IL-6 and VEGF and promoting a pro-angiogenic, pro-inflammatory microenvironment. Pyruvate accumulation from impaired PC activity generates excess mitochondrial ROS, which phosphorylates IκB kinase, liberating NF-κB to drive TNF-α, IL-8, and adhesion molecule expression on endothelial cells. Ammonia buildup — from impaired urea cycle integration — primes the NLRP3 inflammasome, releasing IL-1β and IL-18. Each pathway, individually manageable in healthy physiology, converges in T2DM patients already carrying elevated basal inflammatory burden.

Systemic consequences the review maps out are broad: musculoskeletal fatigue from reduced ATP availability and lactate-impaired muscle contractility; cognitive fog from neuroinflammation driven by HIF-1α–induced microglial activation; accelerated atherosclerosis from NF-κB–driven endothelial dysfunction and foam cell formation; hepatic fibrosis from urea cycle stress and stellate cell activation; and immune inflammaging — where macrophage metabolic reprogramming shifts toward an M1 pro-inflammatory phenotype, impairing pathogen clearance. The review notes that elderly patients and those with renal impairment are at greatest risk, where metformin's reduced clearance amplifies lactate accumulation and lactic acidosis risk.

The clinical picture the authors present is genuinely dual-edged. Short-term metformin use demonstrates well-documented anti-inflammatory benefits — reduced CRP and IL-6 in multiple trials — attributed to AMPK's direct suppression of mTORC1 and favorable shifts in gut microbiota (notably increased Akkermansia muciniphila). These benefits align with interest in metformin as a geroscience intervention (as in the TAME trial). However, the review argues these short-term gains may mask a slow-accumulating 'inflammatory debt' in long-term, high-dose users, particularly those with declining renal function. The authors call for biomarker-guided dosing strategies — monitoring lactate, ammonia, and inflammatory markers — and for trials pairing metformin with antioxidants or cycle-supporting cofactors to preserve waste-clearance capacity while retaining glycemic benefit.